Renzapride is under clinical development by Atlantic Healthcare and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Renzapride’s likelihood of approval (LoA) and phase transition for Systemic Sclerosis (Scleroderma) took place on 06 Nov 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Renzapride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Renzapride (ATL-1251, BRL-24924) is under development for the treatment of diabetic gastroparesis, systemic scleroderma, custic fibrosis and Parkinson's Disease. The drug candidate is administered through oral route in the form of capsule. Renzapride is a gastroprokinetic agent and antiemetic which acts as a full 5-HT4 full agonist and 5-HT3 antagonist. Serotonin (5-HT) receptors play a pivotal role in the maintenance of overall gastrointestinal motor function. It was also under development for the treatment of constipation-predominant IBS (IBS-C) and for mixed-symptom IBS (IBS-M).
Atlantic Healthcare overview
Atlantic Healthcare is a healthcare solution provider that develops and commercializes specialty pharmaceutical products. The company’s product pipeline includes Alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1 (ICAM-1). It provides products for gastrointestinal disorders including inflammatory bowel disease. Atlantic Healthcare is also developing two tablet formulations of alicaforsen, for the treatment of Crohn’s disease and active distal ulcerative colitis. The company commercializes its products in Europe, the US, Canada and Israel Atlantic Healthcare is headquartered in Saffron Walden, Essex, the UK.
Quick View Renzapride LOA Data
|Highest Development Stage|